key: cord-0296442-gxr5dqzf authors: Nantel, S.; Bourdin, B.; Adams, K.; Carbonneau, J.; Rabezanaha, H.; Hamelin, M.-E.; McCormack, D.; Savard, P.; Longtin, Y.; Cheng, M.; DeSerres, G.; Corbeil, J.; Gilca, V.; Baz, M.; Boivin, G.; Quach, C.; Decaluwe, H. title: Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection. date: 2022-04-02 journal: nan DOI: 10.1101/2022.03.29.22272714 sha: 8e5ccce46b7e22a244b16a17ce13d3268e5cef5d doc_id: 296442 cord_uid: gxr5dqzf Importance Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. We present detailed immunological evidence to clarify the requirements for one- or two-dose primary vaccination series for naturally primed individuals. Objective Evaluate the immune response to COVID-19 mRNA vaccines in healthcare workers (HCWs) who recovered from a SARS-CoV-2 infection. Design Multicentric observational prospective cohort study of HCWs with a PCR-confirmed SARS-CoV-2 infection designed to evaluate the dynamics of T and B cells immune responses to primary infection and COVID-19 mRNA vaccination over 12 months. Participants Unvaccinated HCWs with PCR-confirmed SARS-CoV-2 infection were selected based on the presence or absence of symptoms at infection and serostatus at enrollment. Age- and sex-matched adults not infected with SARS-CoV-2 prior to vaccination were included as naive controls. Exposure Vaccination with Pfizer BioNTech BNT162b2 mRNA vaccine. Main Outcome(s) and Measure(s) Immunity score (zero to three), before and after vaccination, based on anti-RBD IgG ratio, serum capacity to neutralize live virus and IFN-{gamma} secretion capacity in response to SARS-CoV-2 peptide pools above the positivity threshold for each of the three assays. We compared the immunity score between groups based on subjects symptoms at diagnosis and/or serostatus prior to vaccination. Results None of the naive participants (n=14) showed a maximal immunity score of three following one dose of vaccine compared to 84% of the previously infected participants (n=55). All recovered individuals who did not have an immunity score of three were seronegative prior to vaccination, and 67% had not reported symptoms resulting from their initial infection. Following one dose of vaccine, their immune responses were comparable to naive individuals, with significantly weaker responses than those who were symptomatic during infection. Conclusions and Relevance Individuals who did not develop symptoms during their initial SARS-CoV-2 infection and were seronegative prior to vaccination present immune responses comparable to that of naive individuals. These findings highlight the importance of administering the complete two-dose primary regimen and following boosters of mRNA vaccines to individuals who experienced asymptomatic SARS-CoV-2 infection. Immunity score (zero to three), before and after vaccination, based on anti-RBD IgG ratio, serum capacity to neutralize live virus and IFN-g secretion capacity in response to SARS-CoV-2 peptide pools above the positivity threshold for each of the three assays. We compared the immunity score between groups based on subjects' symptoms at diagnosis and/or serostatus prior to vaccination. None of the naïve participants (n=14) showed a maximal immunity score of three following one dose of vaccine compared to 84% of the previously infected participants (n=55). All recovered individuals who did not have an immunity score of three were seronegative prior to vaccination, and 67% had not reported symptoms resulting from their initial infection. Following one dose of vaccine, their immune responses were comparable to naïve individuals, with significantly weaker responses than those who were symptomatic during infection. Individuals who did not develop symptoms during their initial SARS-CoV-2 infection and were seronegative prior to vaccination present immune responses comparable to that of naïve individuals. These findings highlight the importance of administering the complete two-dose primary regimen and following boosters of mRNA vaccines to individuals who experienced asymptomatic SARS-CoV-2 infection. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint As of March 2022, more than 450 million people have been infected by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), leading to over six million deaths from Coronavirus Infectious Disease 2019 (COVID-19). [1] [2] [3] The range of symptoms associated with SARS-CoV-2 infection is highly diverse, and the scale of symptoms spans from asymptomatic to severe. 4 Public health vaccination guidelines of adults who have recovered from SARS-CoV-2 infection differ depending on the country. In Canada and the United States, the National Advisory Committee on Immunization (NACI) and the Centers for Disease Control and Prevention (CDC) recommend a two-dose primary regimen for every adult, 5-8 regardless of previous infection status, while countries such as France, Germany, Italy, and Switzerland consider that infection with SARS-CoV-2 is equivalent to one vaccine dose. 9 It remains to be established if vaccine requirements for previously infected subjects differ from those for naïve individuals. Up to one year after their infection, recovered individuals present strong and slowly decaying humoral and cellular responses. [10] [11] [12] [13] Importantly, it was suggested that the strength of the immune response following natural infection is proportional to the disease severity. [14] [15] [16] In previously infected individuals, one vaccine dose a few months after infection acts as a booster of immune responses. 17, 18 It elicits much stronger B-and T-cell-specific responses in previously infected individuals, compared to naïve individuals, with minimal benefits observed when a second dose is given 21 days after the first one. 10, 11, [18] [19] [20] [21] [22] However, it is unknown if individuals who were previously infected, but did not experience symptoms, show similar heightened immune responses after a single mRNA vaccine dose. We hypothesized that the symptom severity during natural infection impacts the response to vaccination and that individuals who did not experience symptoms during infection may present suboptimal protection after one dose of vaccine. In this report, we used three biomarkers of immunity to characterize an effective immune response to SARS-CoV-2. We assessed (1) circulating anti-RBD IgG levels, (2) functional serum capacity to neutralize live SARS-CoV-2 virus and (3) IFN-g secretion by memory cells in response to mega All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint pools of SARS-CoV-2 peptides in a cohort of naïve and previously infected individuals before and after COVID-19 mRNA vaccination. We compared the impact of symptoms at the time of primary infection and serology at enrollment (prior to vaccination) on the immune responses to one and two vaccine doses. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Our cohort consisted of 55 previously infected health care workers (HCWs) who were recruited following a PCR-confirmed SARS-CoV-2 infection as part of the RECOVER study (n=569), 23 and 14 naïve HCWs with neither history of SARS-CoV-2 infection nor the presence of anti-N or anti-RBD antibodies against SARS-CoV-2 prior to vaccination with BNT162b2 mRNA vaccine (Pfizer-BioNTech, 30 µg per dose). Participants were selected based on their symptomatology at the time of infection and their serostatus at enrollment in the study. All RECOVER subjects who were asymptomatic and for whom samples were available before and after vaccination were included in the study (n= 19) . Participants who were symptomatic during infection (n=26) were randomly selected from the rest of the RECOVER cohort based on their serostatus at enrollment after being matched with participants from the asymptomatic group for sex, age, time since infection and time between infection and vaccination. Characteristics of the study population are shown in (eTable1 in Supplemental 1). The severity of the initial SARS-CoV-2 infection was determined using the WHO clinical progression scale. 4 Blood samples for humoral and cellular immunity were collected at enrollment and at different time points after vaccination as described in eFigure 1 in Supplemental 1. Participants were recruited from August 17, 2020, to April 8, 2021, and followed for one year after enrollment. Blood samples were collected into serum separation tubes (SST™, BD) and acid-citrate-dextrose tubes (ACD, BD). They were shipped to the Rare Pediatric Disease (RaPID) biobank at the CHU Sainte-Justine, where serum and peripheral blood mononuclear cells (PBMCs) were isolated according to standard operation procedures (SOPs) using SepMate™ tubes (Stemcell Technologies, Canada) for PBMCs isolation. Serum was cryopreserved at -80°C, and PBMCs were cryopreserved in complete RPMI (Gibco) with 10% DMSO and stored in liquid nitrogen until used. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint Exposure was defined as vaccination with Pfizer BioNTech BNT162b2 mRNA vaccine. Vaccine administration was not part of the study itself, as participants received their vaccines through routine public health programs. The primary outcome was the plurality of immune responses developed after each vaccine dose, represented as an immunity score from zero to three. One point was attributed for each of the following immune assays above positive threshold : anti-RBD IgG levels by ELISA, plasma capacity to neutralize live SARS-CoV-2 (ancestral strain) by microneutralization assay, and IFN-g secretion by PBMCs in response to SARS-CoV-2 mega pool of Spike peptides, determined by ELISpot. An ELISA was performed on serum samples to detect specific IgG antibodies for the Receptor Binding Domain (anti-RBD) of SARS-CoV-2 Spike Glycoprotein as previously described. 24, 25 Seropositivity was defined as an OD490 ratio greater than one with the experimentally determined cut-off, which corresponds to the mean of negative controls plus three times the standard deviation of the negative controls. This anti-RBD IgG ELISA was validated on pre-pandemic samples (negative controls) and samples from subjects with confirmed SARS-CoV-2 infection sent by the Canadian National Microbiology Laboratory. 23 Absence of previous infection to SARS-CoV-2 was confirmed in the naïve cohort by performing an ELISA detecting specific IgG antibodies for the Nucleoprotein (anti-N) of SARS-CoV-2 and the anti-RBD ELISA before vaccination. Neutralizing antibody titers were assessed using SARS-CoV-2/Québec City/21697/2020 strain (ancestral Wuhan-1 like SARS-CoV-2), isolated from a clinical sample in March 2020 in Québec City, Canada. Two-fold dilutions of heat-inactivated serum were prepared, starting with 1:20 dilution. Equal volumes of serum and virus were mixed and incubated for one hour at room temperature. The residual infectivity of those mixtures was assessed in quadruplicate wells of African green monkey kidney E6 cell line (Vero ATCC® CRL-1586 TM ). Neutralizing antibody titers All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint were defined as the reciprocal of the serum dilution that completely neutralized the infectivity of 100 TCID50 of SARS-CoV-2, determined by the absence of cytopathic effect on cells after four days. 26 The neutralizing antibody titer is calculated using the Reed/Muench method. 27 These studies were performed in the Containment Level 3 (CL3) laboratory at the CHU de Québec-Université Laval. Cell-mediated immune (CMI) response was estimated by ELISpot. Frozen PBMCs were rapidly thawed and rested overnight. They were then stimulated with 1 µg/mL of spike glycoprotein (S), nucleocapsid protein (NCAP) or membrane protein (VME1) mega pools of SARS-CoV-2 peptides from the ancestral Wuhan-1 like strain (JPT Peptide Technologies, JPT) as described elsewhere. 28 Spots were revealed using BIO-RAD Alkaline Phosphatase Conjugate Substrate Kit. The resulting ELISpots were analyzed using CTL ImmunoSpot® S5 UV Analyzer (Cellular Technology Ltd, OH). Culture media and phytohemagglutinin (PHA, Sigma) were used as negative and positive controls, respectively. The positive threshold response was defined as more than 25 spot-forming units (SFU) per million cells. Thawed and rested PBMCs were stimulated for 20 hours with 1 µg/mL of the CD4-Spike peptides mega pool developed and synthesized by the Sette laboratory. 29, 30 Constituted of 246 HLA-class II conditions were used to set the gates for each participant. Results are represented by the frequency All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. of activated cells following peptide stimulation minus the frequency of activated cells in the unstimulated condition. All statistical tests were performed using Prism 9, version 9.2.0 (2021 GraphPad Software, LLC) and data were displayed as mean ± SEM. Wilcoxon-Mann-Whitney or Kruskal-Wallis tests were used to evaluate statistical significance between groups for variables that did not follow a normal distribution. Simple linear regression is presented with Pearson correlation (R 2 ) and P-value (p). Significance was set as *p <.05; **p <.01; ***p <.001; ****p <.0001. RECOVER protocols were approved by the Research Ethics Board (REB) at the CHU Sainte-Justine (CHUSJ) under study MP-21-2021-3035 and in each of the five participating centers in the Province of Québec. Written informed consent was obtained from all participants during the recruitment period, and ongoing consent was reviewed at each subsequent visit. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The RECOVER cohort consists of 569 HCWs infected with SARS-CoV-2 during the first and second pandemic waves. 23 Overall, 95% of participants had symptoms at the time of diagnosis (n=541), and very few were asymptomatic (n=28). Among asymptomatic subjects, only 43% were seropositive at enrollment, in contrast to 77% of symptomatic individuals (eFigure 3A in Cell-mediated immune responses to the major components of SARS-CoV-2 were also assessed in almost half of the RECOVER cohort (n=200) by ELISpot. Responses to Spike, NCAP and VME1 were present and maintained up to one year after natural infection in the majority of participants (84%, 80% and 72% respectively), with the most potent response being specific for Spike antigens (140.3 ± 12.7 SFU/10 6 PBMCs, compared to 86.17 ± 6.7 and 95.04 ± 9.4 SFU/10 6 PBMCs for NCAP and VME1) (eFigure 4 in Supplemental 1). We selected a subset of individuals (n=55) to study the impact of previous infection on the immune response to vaccination. All subjects received the BNT162b2 Pfizer BioNTech COVID-19 vaccine, with a first dose administered 8.4 ± 2.3 months (range: 0.8-13.1 months) after infection (eTable2 in Supplemental 1). The second dose was offered 16 ± 6 weeks after the first dose. Samples were collected before vaccination, around 45 ± 25 days and 57 ± 30 days after the first and second dose, respectively. They were compared to 14 previously naïve individuals before vaccination, 29 ± 2 days after the first vaccine dose and 35 ± 5 days after the second dose. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint Prior to vaccination, most recovered HCWs presented detectable anti-RBD IgG levels (1.6 ± 0.2) and IFN-g responses to Spike antigens (135.9 ± 30.1 SFU/10 6 PBMCs), while serum neutralization capability was mainly absent or low. It has been demonstrated that a well-coordinated humoral and cellular immune response, with the development of both antibody neutralizing capacity and cell-mediated immune responses, protects against severe disease. 14,15 In previously infected HCWs vaccinated with one dose, we observed that the strength of the cellular response, as assessed by ELISpot assay, correlates positively with both RBD-binding IgG and SARS-CoV-2 neutralizing antibody titers (eFigure 6 in Supplemental 1), with the strongest correlation being between IFN-g response and neutralization capacity. This suggests that vaccine-induced immune protection relies on a synchronized adaptive immune response. 31, 32 To better depict the global immune response of each subject, we calculated an immunity score based on the presence or absence of RBD-binding antibodies, SARS-CoV-2 neutralizing antibodies and CMI response for each participant. We showed that none of the naïve individuals had a global immunity score of three after one dose of vaccine ( Figure 1B) . In contrast, 84% of the previously infected individuals reached the maximal immunity score, the remainder showing an incomplete response and 6% demonstrating nearly no response ( Figure 1B) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. (Figure 2A) . Importantly, asymptomatic individuals were less likely to neutralize SARS-CoV-2 after one dose of vaccine compared to symptomatic subjects (68% vs. 97%, P=.007). Furthermore, 92% of symptomatic individuals showed a global immune response with an immunity score of three after their first dose of vaccine compared to 69% of asymptomatic individuals ( Figure 2B ). In our RECOVER cohort, 24.6% (n = 140) of recovered HCWs were seronegative at enrollment in the study. 23 We thus questioned if serostatus at enrollment, 3.0 ± 1.5 months prior to vaccination, 125.2 ± 27.1, P<.001) after one dose of vaccine ( Figure 3A) . Importantly, subjects who did not mount a positive humoral and/or cellular response after one dose of vaccine were all seronegative before vaccination. One dose of vaccine was only sufficient to boost immunity to SARS-CoV-2 in 63% of seronegative participants ( Figure 3B) . The others showed reduced capability to mount adequate neutralization of the virus and/or cell-mediated immune response, and two subjects remained nonresponsive. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Most previously infected HCWs who did not develop an immunity score of three after the first dose of vaccine had an asymptomatic SARS-CoV-2 infection (6 out of 9; Figure 2B ). To better depict the impact of seropositivity and symptomatology on the immune response to one dose of vaccine, we compared levels of induced immunity within each subgroup. Symptomatic individuals who remained seropositive following natural infection developed the most vigorous humoral and cellular immune response to one dose of vaccine ( Figure 4A-B) . Furthermore, their frequency of SARS-CoV-2 specific CD4 + T cells, as assessed by the expression of activation markers, was the highest Among HCWs who recovered from SARS-CoV-2 infection, 16 % did not demonstrate a wellcoordinated humoral and cellular immune response after one vaccine dose ( Figure 1B) , with asymptomatic, seronegative subjects being the least responsive. Therefore, we assessed humoral and cellular responses after the second dose of vaccine. Strikingly, all subjects displayed a strong humoral and cellular immune response after two doses of vaccine, including naïve and asymptomatic participants, as demonstrated by elevated anti-RBD IgG levels, neutralizing capability, as well as IFN-g secreting cells (Figure 5A and eFigure 8 in Supplemental 1) . After two doses of vaccine, naïve individuals still showed slightly lower anti-RBD IgG levels compared to All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint both asymptomatic and symptomatic recovered individuals (Figure 5B) . Cellular responses remained lower in asymptomatic HCWs compared to their symptomatic counterparts (Figure 5B) . Our results collectively demonstrate that the severity of initial infection leads to the development of a more robust and persistent immune memory response after a vaccination challenge. In contrast, individuals that did not experience symptoms during infection with SARS-CoV-2 are less likely to develop long-term humoral and cellular immunity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The ultimate goal of vaccination is to generate broad and long-lasting immune responses that will protect the host from severe clinical outcomes if infected. The most appropriate vaccination regimen to be used in previously infected individuals remains undefined, leading to discrepancies in public health recommendations worldwide. Based on prior studies suggesting that previously infected individuals did not benefit from their second dose of mRNA vaccine, 18,22 many countries have moved forward with the recommendation that a single dose of mRNA vaccine was sufficient for individuals who were previously infected. 9 In this report, we demonstrate that one dose of vaccine is sufficient to induce sustained humoral and cellular immune responses in 92% of previously infected individuals who experienced symptoms during their infection. In contrast, only 69% in individuals who remained asymptomatic during their primary infection mounted robust immune responses to one dose of vaccine. In fact, infected individuals who remained asymptomatic and were seronegative at enrollment in our study harbored an immune response comparable to naïve subjects before and after vaccination. This is true even when using an extended vaccination regimens shown to favor better immune memory, 33 as our cohort was vaccinated with a 16-week interval between each vaccine dose. Our results differ from one American HCWs cohort that concluded that humoral immune responses shortly after one mRNA vaccine dose were comparable in individuals that recovered from symptomatic and asymptomatic infections. 34 However, HCWs from that cohort were all seropositive at the time of vaccination. Here, we show that previously infected but asymptomatic individuals that harbour a negative serostatus at vaccination mount reduced serum neutralization capabilities and cell-mediated memory responses following one vaccine dose. Our report supports the requirement for a complete vaccination regimen for adequate protection of individuals who do not experience symptoms during their SARS-CoV-2 infection. Knowledge gained from this study is particularly important in the current context of booster vaccination and protection against recent variants-of-concerns (VOCs). Waning immunity has been reported six months after a two-dose primary series in naïve individuals. 35, 36 In these naïve individuals, three doses of vaccine increase protection against symptomatic and severe B.1.617.2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint (Delta) and B.1.1.529 (Omicron) infections. [37] [38] [39] [40] [41] [42] Notably, despite strengthened immune responses following the booster dose, the capacity to neutralize the B.1.1.529 variant appears weaker. [43] [44] [45] [46] A German study reported that neutralizing antibodies against the Omicron variant were highest in individuals who had encountered the antigen three times, having received two doses of vaccine and having been infected with SARS-CoV-2 prior to or subsequent to vaccination (hybrid immunity) or having received three doses of mRNA vaccine for uninfected individuals. 47 Based on our current report, previously infected individuals who did not develop symptoms should be prioritized in getting a booster shot, as should be previously uninfected ones, as we demonstrate that a fraction of these individuals harbor immune responses to vaccination comparable to naïve individuals. Further studies will be required to evaluate the vaccine requirements for boosters in recently infected Omicron cases, as people infected with this variant are more likely to be asymptomatic. 48 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint Results of this study were obtained from a cohort of primarily middle-aged Caucasian females infected with SARS-CoV-2 eight months before vaccination. It remains to be evaluated if a shorter time between infection and vaccination will lead to similar results. Our study is also limited by a relatively small sample size of participants who did not experience symptoms during their initial infection. It will be essential to validate our findings in a larger population of subjects, as immune responses to SARS-CoV-2 are known to be highly heterogeneous. Furthermore, the protection induced by booster doses against VOCs in previously infected individuals remains to be evaluated. This study did not assess the impact of other approved adenovirus or mRNA vaccines against SARS-CoV-2 49,50 , as primary series or boosters, as well as natural infection with emerging SARS-CoV-2 VOCs, as most of the cohort was infected at the beginning of 2020. 51 Finally, the immunity score may underestimate the quality of the immune memory generated in recovered individuals since it is limited to three of the most standardized assays to interrogate immune response to SARS-CoV-2. Detailed functional, transcriptomic and repertoire analyses will be essential to fully grasp the immune memory differences between individuals who experienced symptoms or not following infection. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This report reveals the critical importance of the impact of an individual's symptomatology at the time of infection and serostatus at the time of vaccination on the capacity to mount adequate immune protection, including cell-mediated responses. In contrast to individuals who were symptomatic during infection, we demonstrated that a third of the individuals who recovered from an asymptomatic infection responded like naïve individuals. Two doses of vaccine should be offered to previously infected but asymptomatic individuals to elicit a global and sustained adaptive immune response following mRNA vaccination. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wratil PR, Stern M, Priller A, et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nature Medicine. 2022. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. assessed by ELISpot for naïve (n=14) and recovered HCWs (n=55) before (white circles) and after one dose of vaccine (black circles). The black line indicates the positive threshold value, and the percentage of individuals with responses above positive threshold value is indicated for each time point. Statistical significance was assessed by Wilcoxon-Mann-Whitney tests. *P <.05; **P <.01; ***P <.001; ****P <.0001. (B) Pie charts of calculated immunity score for naïve (n=14) and recovered HCWs (n=55) before and after one dose of vaccine. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (A) SARS-CoV-2 Spike RBD-specific binding IgG levels assessed by ELISA (left panel), SARS-CoV-2 neutralizing antibody titers (middle panel), and IFN-γ secreting cells per million in response to SARS-CoV-2 Spike glycoprotein peptides assessed by ELISpot (right panel) for naïve (black circles), seronegative (Seroneg.) (n=24) and seropositive (Seropos.) (n=31) recovered HCWs after one dose of vaccine. Asymptomatic recovered HCWs (Asympt.) are represented with green circles (n=19) and symptomatic HCWs (Sympt.) with yellow circles (n=36). The black line indicates the positive threshold value, and the percentage of HCWs with responses above positive threshold value is indicated for each assay. (B) Pie charts of calculated immunity score for asymptomatic (left panel) and symptomatic (right panel) recovered HCWs after one dose of vaccine. (C) Frequency of SARS-CoV-2−Spike-specific T cells measured as percentage of OX40 + CD137 + non-naïve CD4 + (left panel) and CD69 + CD137 + non-naïve CD8 + T cells (right panel) after stimulation of PBMCs with CD4-S mega pool of peptides from the Spike glycoprotein for naïve (n=13), asymptomatic seronegative (n=9) or seropositive (n=10) and symptomatic seronegative (n=12) or seropositive (n=13) recovered HCWs after one dose of vaccine. Error bars indicate mean ± SEM. Statistical significance was assessed by Kruskal-Wallis (A-C). *P <.05; **P <.01; ***P <.001; ****P <.0001. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint Figure 5 : Two doses of vaccine are required for individuals who recovered from an asymptomatic SARS-CoV-2 infection to generate a global and coordinated adaptive immune response. (A) SARS-CoV-2 Spike RBD-specific binding IgG levels assessed by ELISA (left panel), SARS-CoV-2 neutralizing antibody titers (middle panel), IFN-γ secreting cells per million in response to SARS-CoV-2 Spike glycoprotein peptides (right panel) assessed by ELISpot for naïve (n=14), asymptomatic (n=17) and symptomatic recovered HCWs (n=25) before (white circles), after one dose (black circles) and after two doses of vaccine (green circles). (B) SARS-CoV-2 Spike RBD-specific binding IgG levels assessed by ELISA (left panel), SARS-CoV-2 neutralizing antibody titers (middle panel), and IFN-γ secreting cells per million in response to SARS-CoV-2 Spike glycoprotein peptides assessed by ELISpot (right panel) for naïve (black circles), asymptomatic (n=17) and symptomatic (n=25) recovered HCWs after two doses of vaccine. The black line indicates the positive threshold value. Error bars indicate mean ± SEM. Kruskal-Wallis tests assessed statistical significance. *P <.05; **P <.01; ***P <.001; ****P <.0001. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 2, 2022. ; https://doi.org/10.1101/2022.03.29.22272714 doi: medRxiv preprint Clinical features of patients infected with 2019 novel coronavirus in Wuhan Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine A minimal common outcome measure set for COVID-19 clinical research. The Lancet Infectious diseases Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2 COVID-19 treatment guidelines -Prevention of SARS-CoV-2 infection, Prevention of SARS-CoV-2 Infection. Feb 1, 2022. 8. (PHAC) PHAoC. Canadian Immunization Guide -COVID-19 vaccin Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA Persistent Cellular Immunity to SARS-CoV-2 Infection. bioRxiv : the preprint server for biology Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. medRxiv Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection Correlates of protection against SARS-CoV-2 in rhesus macaques Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19 First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19 mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers A serological assay to detect SARS-CoV-2 seroconversion in humans SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets A simple method of estimating fifty per cent endpoints Development of an IFN-γ ELISpot assay to assess varicella-zoster virus-specific cellmediated immunity following umbilical cord blood transplantation A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2 Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. The New England journal of medicine Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence -25 Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study. medRxiv Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination Divergent SARS CoV-2 Omicronreactive T-and B cell responses in COVID-19 vaccine recipients Superior immunity that allows neutralization of all SARS-CoV-2 variants of concern develops in COVID-19 convalescents and naïve individuals after three vaccinations High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron SARS-CoV-2 Vaccines COVID-19 vaccines: where we stand and challenges ahead